aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
aTyr Pharma NASDAQ: ATYR said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting.
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting
aTyr Pharma (NASDAQ: ATYR) CEO Sanjay Shukla outlined the company's strategy to develop new therapies for inflammation and fibrosis based on tRNA synthetase biology during a presentation at the Leerink Partners Global Healthcare Conference. Shukla focused primarily on efzofitimod, the company's lead program, including results from a global Phase 3 study in pulmonary sarcoidosis and the
ATyr Pharma, Inc. (ATYR) Announces Top Line Results For The Phase III EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis (Transcript)
aTyr Pharma, Inc. (NASDAQ:ATYR ) Announces Top Line Results for the Phase III EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis September 15 2025 11:00 AM EDT Company Participants Ashlee Dunston - Director of Investor Relations & Corporate Communications Sanjay Shukla - President, CEO & Director Robert Bachman Jill Broadfoot - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Jiale Song - Jefferies LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating
aTyr Pharma's pivotal data readouts in 2025 for SSc-ILD (Phase 2) and pulmonary sarcoidosis (Phase 3) could significantly impact its market potential and approval prospects. Efzofitimod shows promise in reducing fibrosis without immunosuppression, with recent safety data and a peer-reviewed publication bolstering confidence in its efficacy. Institutional ownership has surged to nearly 80%, indicating strong institutional confidence despite the inherent risks associated with earlier trial failures.
aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript
aTyr Pharma, Inc. (NASDAQ:ATYR ) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Ashlee Dunston - Senior Director of Investor Relations and Public Affairs Sanjay Shukla - President and Chief Executive Officer Leslie Nangle - Vice President of Research Jill Broadfoot - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo & Company Yasmeen Rahimi - Piper Sandler Companies Faisal Khurshid - Leerink Partners LLC Prakhar Agrawal - Cantor Fitzgerald, L.P. Gregory Renza - RBC Capital Markets Joe Pantginis - H.C.
aTyr Pharma: The Bull Has Finally Come Out
aTyr Pharma has a pivotal year ahead with key readouts for Efzofitimod in pulmonary sarcoidosis and SSC-ILD, potentially opening a huge market. Efzofitimod aims to modulate inflammation without immune suppression, setting it apart from traditional treatments, with promising post-hoc results in higher doses. aTyr is well-funded with $81 million in cash, sufficient for upcoming trial readouts, and has seen significant stock performance and insider buying.
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
Topline data from phase 3 EFZO-FIT study, using efzofitimod for the treatment of patients with pulmonary sarcoidosis, expected Q3 of 2025. The 7 major pulmonary sarcoidosis markets are expected to reach a value of $53.3 billion by 2034. Topline data from the phase 2 EFZO-CONNECT study, using efzofitimod for the treatment of patients with scleroderma-related ILD, expected Q2 of 2025.
